Catálogo de publicaciones - revistas
Alzheimer's and Dementia: The Journal of the Alzheimer's Association
Resumen/Descripción – provisto por la editorial en inglés
The mission of Alzheimer's & Dementia: Journal of the Alzheimer's Association is to bridge the knowledge gaps across a wide range of bench-to-bedside investigation. The journal publishes the results of studies in: behavior, biochemistry, genetics, molecular biology, pharmacology, physiology, protein chemistry, neurology, neuropathology, psychiatry, geriatrics, neuropsychology, epidemiology, sociology, health services research, health economics, political science and public policy. Content emphasizes interdisciplinary investigations, integrative/translational articles, related to: etiology, risk factors, early detection, disease modifying interventions, prevention of dementia and applications of new technologies in health services. The journal publishes • comprehensive reviews; • research articles; • information on clinical trials; • short reports;• in-depth perspectives/open-peer commentaries; • theoretical and/or translational papers that attempt integrate knowledge across discipline;
• history & politics of science/brief biographies and, • abstracts of papers presented at international meetings. Negative results, particularly clinical trials, are published as short communications.
The ultimate objective is to create a novel forum for: • rapid communication of new findings, ideas or perspectives; • disseminating knowledge, across the spectrum of basic to clinical studies, necessary for optimal translation of research findings into practical applications/interventions; • integrating knowledge across disciplines; • increase knowledge in diverse disciplines to promote early detection/diagnosis and/or interventions; • formulating new theories and/or strategies for the rigorous testing of theories or their predictions; • identifying promising new directions of research and, • providing the scientific impetus for new initiatives; or public policies concerning research on prevention and new models of health services.
Alzheimer's & Dementia is indexed/abstracted in Index Medicus/MEDLINE, Scopus, Science Citation Index Expanded (SciSearch®), Current Contents®/Clinical Medicine, Neuroscience Citation Index®, and Journal Citation Reports/Science Edition.
Palabras clave – provistas por la editorial
No disponibles.
Disponibilidad
| Institución detectada | Período | Navegá | Descargá | Solicitá |
|---|---|---|---|---|
| No detectada | desde ene. 2005 / hasta dic. 2023 | Wiley Online Library |
Información
Tipo de recurso:
revistas
ISSN impreso
1552-5260
ISSN electrónico
1552-5279
Editor responsable
Elsevier
País de edición
Países Bajos
Fecha de publicación
2005-
Cobertura temática
Tabla de contenidos
Mild cognitive impairment and cognitive impairment, no dementia: Part B, therapy
Fadi Massoud; Sylvie Belleville; Howard Bergman; John Kirk; Howard Chertkow; Ziad Nasreddine; Yves Joanette; Morris Freedman
Palabras clave: Health Policy; Developmental Neuroscience; Epidemiology; Cellular and Molecular Neuroscience; Geriatrics and Gerontology; Psychiatry and Mental health; Clinical Neurology.
Pp. 283-291
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Guy M. McKhann; David S. Knopman; Howard Chertkow; Bradley T. Hyman; Clifford R. Jack; Claudia H. Kawas; William E. Klunk; Walter J. Koroshetz; Jennifer J. Manly; Richard Mayeux; Richard C. Mohs; John C. Morris; Martin N. Rossor; Philip Scheltens; Maria C. Carrillo; Bill Thies; Sandra Weintraub; Creighton H. Phelps
<jats:p>The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of revising the 1984 criteria for Alzheimer's disease (AD) dementia. The workgroup sought to ensure that the revised criteria would be flexible enough to be used by both general healthcare providers without access to neuropsychological testing, advanced imaging, and cerebrospinal fluid measures, and specialized investigators involved in research or in clinical trial studies who would have these tools available. We present criteria for all‐cause dementia and for AD dementia. We retained the general framework of probable AD dementia from the 1984 criteria. On the basis of the past 27 years of experience, we made several changes in the clinical criteria for the diagnosis. We also retained the term possible AD dementia, but redefined it in a manner more focused than before. Biomarker evidence was also integrated into the diagnostic formulations for probable and possible AD dementia for use in research settings. The core clinical criteria for AD dementia will continue to be the cornerstone of the diagnosis in clinical practice, but biomarker evidence is expected to enhance the pathophysiological specificity of the diagnosis of AD dementia. Much work lies ahead for validating the biomarker diagnosis of AD dementia.</jats:p>
Pp. 263-269
Trajectories of Alzheimer disease-related cognitive measures in a longitudinal sample
Murat Bilgel; Yang An; Andrew Lang; Jerry Prince; Luigi Ferrucci; Bruno Jedynak; Susan M. Resnick
Palabras clave: Health Policy; Developmental Neuroscience; Epidemiology; Cellular and Molecular Neuroscience; Geriatrics and Gerontology; Psychiatry and Mental health; Clinical Neurology.
Pp. 735-742.e4
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
Frank Jessen; Rebecca E. Amariglio; Martin van Boxtel; Monique Breteler; Mathieu Ceccaldi; Gaël Chételat; Bruno Dubois; Carole Dufouil; Kathryn A. Ellis; Wiesje M. van der Flier; Lidia Glodzik; Argonde C. van Harten; Mony J. de Leon; Pauline McHugh; Michelle M. Mielke; Jose Luis Molinuevo; Lisa Mosconi; Ricardo S. Osorio; Audrey Perrotin; Ronald C. Petersen; Laura A. Rabin; Lorena Rami; Barry Reisberg; Dorene M. Rentz; Perminder S. Sachdev; Vincent de la Sayette; Andrew J. Saykin; Philip Scheltens; Melanie B. Shulman; Melissa J. Slavin; Reisa A. Sperling; Robert Stewart; Olga Uspenskaya; Bruno Vellas; Pieter Jelle Visser; Michael Wagner;
<jats:title>Abstract</jats:title><jats:sec><jats:label/><jats:p>There is increasing evidence that subjective cognitive decline (SCD) in individuals with unimpaired performance on cognitive tests may represent the first symptomatic manifestation of Alzheimer's disease (AD). The research on SCD in early AD, however, is limited by the absence of common standards. The working group of the Subjective Cognitive Decline Initiative (SCD‐I) addressed this deficiency by reaching consensus on terminology and on a conceptual framework for research on SCD in AD. In this publication, research criteria for SCD in pre‐mild cognitive impairment (MCI) are presented. In addition, a list of core features proposed for reporting in SCD studies is provided, which will enable comparability of research across different settings. Finally, a set of features is presented, which in accordance with current knowledge, increases the likelihood of the presence of preclinical AD in individuals with SCD. This list is referred to as SCD <jats:italic>plus</jats:italic>.</jats:p></jats:sec>
Pp. 844-852
Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease
Rachel F. Buckley; Paul Maruff; David Ames; Pierrick Bourgeat; Ralph N. Martins; Colin L. Masters; Stephanie Rainey-Smith; Nicola Lautenschlager; Christopher C. Rowe; Greg Savage; Victor L. Villemagne; Kathryn A. Ellis;
Palabras clave: Health Policy; Developmental Neuroscience; Epidemiology; Cellular and Molecular Neuroscience; Geriatrics and Gerontology; Psychiatry and Mental health; Clinical Neurology.
Pp. 796-804
P2-233: BETTER MEASUREMENT FOR IMPROVED DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE: UPDATE ON THE EMPIR NEUROMET PROJECT
Milena Quaglia; Vittorio Bellotti; Stefan Cano; Adam Cryar; Katherine Deane; Carla Divieto; Ariane Fillmer; Chiara Giangrande; Theresa Köbe; Sylvain Lehmann; Jeanette Melin; Susan Pang; Helen Parkes; Leslie Pendrill
Palabras clave: Health Policy; Developmental Neuroscience; Epidemiology; Cellular and Molecular Neuroscience; Geriatrics and Gerontology; Psychiatry and Mental health; Clinical Neurology.
Pp. P759-P760
Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale
Michael Navitsky; Abhinay D. Joshi; Ian Kennedy; William E. Klunk; Christopher C. Rowe; Dean F. Wong; Michael J. Pontecorvo; Mark A. Mintun; Michael D. Devous
<jats:title>Abstract</jats:title><jats:sec><jats:title>Introduction</jats:title><jats:p>Klunk et al. recently proposed a means of standardizing quantitation of amyloid burden from positron emission tomography scans to a common Centiloid scale, and we have applied that method to florbetapir.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Florbetapir and Pittsburgh compound B scans were acquired for 46 mixed clinical presentation subjects within 18 ± 20 days. Florbetapir and Pittsburgh compound B cortical standardized uptake value ratio (SUVr) values were well correlated for both standard Centiloid (R<jats:sup>2</jats:sup> = 0.894) and Avid (R<jats:sup>2</jats:sup> = 0.901) volume of interests (VOIs). The methods of Klunk et al. were applied to establish a conversion first from florbetapir SUVr values obtained using standard Centiloid VOIs to Centiloids and then from Avid VOIs (Joshi et al.) to Centiloids.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The equation for conversion of florbetapir SUVr from Avid VOIs to the Centiloid scale was as follows: Florbetapir Centiloids = 183 × SUVr<jats:sub>Avid</jats:sub> − 177. The threshold that discriminated neuropathologically verified none or sparse versus moderate to frequent plaques in autopsy‐confirmed data is 24.1 Centiloids.</jats:p></jats:sec><jats:sec><jats:title>Discussion</jats:title><jats:p>These findings may allow improved tracer‐independent amyloid quantitation.</jats:p></jats:sec>
Pp. 1565-1571
doi: 10.1002/alz.058593
Accelerated epigenetic aging in adults with Down Syndrome in the Argentine population
Giulia Solange Clas; Elmer A. Fernández; Juan Carlos Guillermo Vázquez; Lucia Pertierra; Nahuel Magrath Guimet; Fernanda Tapajoz; Belén Helou; Tatiana Itzcovich; Micaela Barbieri Kennedy; Horacio Martinetto; Gustavo Sevlever; Ricardo Francisco Allegri; Ezequiel Surace
Palabras clave: Psychiatry and Mental health; Cellular and Molecular Neuroscience; Geriatrics and Gerontology; Neurology (clinical); Developmental Neuroscience; Health Policy; Epidemiology.
Pp. No disponible
doi: 10.1002/alz.12505
Different rates of cognitive decline in autosomal dominant and late‐onset Alzheimer disease
Virginia D. Buckles; Chengjie Xiong; Randall J. Bateman; Jason Hassenstab; Ricardo Allegri; Sarah B. Berman; Jasmeer P. Chhatwal; Adrian Danek; Anne M. Fagan; Bernardino Ghetti; Alison Goate; Neill Graff‐Radford; Mathias Jucker; Johannes Levin; Daniel S. Marcus; Colin L. Masters; Lena McCue; Eric McDade; Hiroshi Mori; Krista L. Moulder; James M. Noble; Katrina Paumier; Oliver Preische; John M. Ringman; Nick C. Fox; Stephen Salloway; Peter R. Schofield; Ralph Martins; Jonathan Vöglein; John C. Morris;
Palabras clave: Psychiatry and Mental health; Cellular and Molecular Neuroscience; Geriatrics and Gerontology; Neurology (clinical); Developmental Neuroscience; Health Policy; Epidemiology.
Pp. No disponible
doi: 10.1002/alz.12644
Changes in cognitive functioning after COVID‐19: A systematic review and meta‐analysis
Lucia Crivelli
; Katie Palmer; Ismael Calandri; Alla Guekht; Ettore Beghi; William Carroll; Jennifer Frontera; David García‐Azorín; Erica Westenberg; Andrea Sylvia Winkler; Francesca Mangialasche; Ricardo F. Allegri; Miia Kivipelto
Palabras clave: Psychiatry and Mental health; Cellular and Molecular Neuroscience; Geriatrics and Gerontology; Neurology (clinical); Developmental Neuroscience; Health Policy; Epidemiology.
Pp. No disponible